In a multi-center, phase 1 study in which we participated to determine the efficacy of LCAR-B38M, a CAR-T product targeting B cell maturation antigen (BCMA), in relapsed and/or refractory MM (RRMM) (Clinicaltrials.gov NO. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.